Pediatric Polyhydramnios and Oligohydramnios Workup

  • Author: Brian S Carter, MD, FAAP; Chief Editor: Ted Rosenkrantz, MD   more...
 
Updated: Feb 24, 2012
 

Laboratory Studies

If premature delivery is anticipated with either oligohydramnios or polyhydramnios, the amniotic fluid lamellar body count, lecithin-sphingomyelin (L:S) ratio, and phosphatidylglycerol (PG) concentration are helpful in determining the maturity of the fetal lungs and, therefore, in assessing the likelihood of respiratory distress syndrome.

  • Polyhydramnios
    • Glucose tolerance test for mothers with suspected type 2 diabetes mellitus
    • Fetal hydrops testing: If fetal hydrops is present, immunologic and fetal infection need to be investigated. This should include screening for maternal antibodies to D, C, Kell, Duffy, and Kidd antigens to determine maternal antibody production against the fetal red blood cells. Infections of the fetus include cytomegalovirus (CMV), toxoplasmosis, syphilis, and parvovirus B19. The investigation should include the following:
      • Venereal Disease Research Laboratories (VDRL) test to screen for syphilis
      • Immunoglobulin G (IgG) and immunoglobulin M (IgM) titers to evaluate for exposure to rubella, CMV, toxoplasmosis and parvovirus
      • A test for congenital viruses in the amniotic fluid using the polymerase chain reaction
    • Kleihauer-Betke test to evaluate fetal-maternal hemorrhage
    • Hemoglobin Bart in patients of Asian descent (who may be heterozygous for alpha-thalassemia)
    • Fetal karyotyping for trisomy 21, 13, and 18
  • Oligohydramnios
    • Test for systemic lupus erythematosus, which causes immune-mediated infarcts in the placenta and placental insufficiency.
    • Evaluate for PIH and hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome. Test for elevated blood pressure, proteinuria, elevated uric acid, increased liver function test results, and low platelet count.
Next

Imaging Studies

  • Prenatal ultrasonography and polyhydramnios
    • Evaluate fetal swallowing. A decrease in fetal deglutition occurs in anencephaly, trisomy 18, trisomy 21, muscular dystrophy, and skeletal dysplasia.
    • Evaluate the fetal anatomy; assess for diaphragmatic hernia, lung masses, and the absence of the stomach bubble (which is associated with esophageal atresia). The double-bubble sign or a dilated duodenum suggests the possibility of duodenal atresia.
    • Test for fetal arrhythmias and malformations that result in cardiac failure and hydrops.
    • An abnormally large abdominal circumference may be observed with ascites and hydrops fetalis.
    • A macrosomic fetus is observed in association with poorly controlled maternal diabetes.
    • Assess the blood flow velocity in the anterior cerebral artery of the fetus for fetal anemia.
  • Prenatal ultrasonography and oligohydramnios
    • Perform serial measurements of the AFI during the pregnancy. If the mother is in the third trimester and if the volume is less than 8 cm, suspect oligohydramnios. Levels less than 5 cm indicate significant oligohydramnios.
    • Visualize the fetal kidneys, collecting system, and bladder. If these are normal, suspect the chronic leakage of amniotic fluid or PIH.
    • Assess fetal growth. If PROM or urinary tract anomalies are absent, consider placental insufficiency and IUGR.
    • Uterine artery Doppler study findings may aid in the diagnosis of placental insufficiency.
    • Postnatally, evaluate organ systems likely to be involved on the basis of the pregnancy history and results of other prenatal evaluations. For more information, see Oligohydramnios.
Previous
Next

Other Tests

  • Testing of the infant is recommended, depending on the results of postnatal evaluation of the infant. Such evaluation may include chromosome testing, testing for evidence of congenital infection, ultrasonography of the genitourinary tract, and appropriate radiologic evaluation of the GI tract. ECG and echocardiography may also be indicated.
Previous
Next

Procedures

  • Polyhydramnios
    • Reductive amniocentesis may be performed and has contributed to prolonged pregnancy in patients who are severely affected by hydramnios.[6] This procedure can reduce the risk of preterm labor, PROM, umbilical cord prolapse, and placental abruption. However, if too much fluid is removed, placental abruption may occur. Other risks of the procedure include infection, bleeding, and trauma to the fetus.
    • Laser ablation of placental vessels may be efficacious in cases of twin-to-twin transfusion syndrome.
  • Oligohydramnios
    • The transabdominal instillation of indigo carmine may be used to evaluate for PROM.
    • The transcervical instillation of isotonic sodium chloride solution (ie, amnioinfusion) at the time of delivery reduces the risk of cord compression, fetal distress and meconium dilution. It also reduces the potential need for cesarean delivery.
Previous
Next

Histologic Findings

  • Examination of the placenta may be helpful in determining the cause of the polyhydramnios or oligohydramnios.
Previous
 
 
Contributor Information and Disclosures
Author

Brian S Carter, MD, FAAP  Professor of Pediatrics (Neonatology), Vanderbilt University School of Medicine; Director, Neonatal Follow-up Program, Monroe Carell Jr Children's Hospital at Vanderbilt

Brian S Carter, MD, FAAP is a member of the following medical societies: Alpha Omega Alpha, American Academy of Hospice and Palliative Medicine, American Academy of Pediatrics, American Society for Bioethics and Humanities, American Society of Law, Medicine & Ethics, National Hospice and Palliative Care Organization, Society for Pediatric Research, and Southern Society for Pediatric Research

Disclosure: Nothing to disclose.

Coauthor(s)

Roland L Boyd, DO  Neonatologist, Section of Neonatology, Neonatal Services, Ltd

Roland L Boyd, DO is a member of the following medical societies: American Academy of Osteopathy, American Academy of Pediatrics, and American College of Osteopathic Pediatricians

Disclosure: Nothing to disclose.

Specialty Editor Board

Ted Rosenkrantz, MD  Professor, Departments of Pediatrics and Obstetrics/Gynecology, Division of Neonatal-Perinatal Medicine, University of Connecticut School of Medicine

Ted Rosenkrantz, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Pediatric Society, Connecticut State Medical Society, Eastern Society for Pediatric Research, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

David A Clark, MD  Chairman, Professor, Department of Pediatrics, Albany Medical College

David A Clark, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Pediatric Society, Christian Medical & Dental Society, Medical Society of the State of New York, New York Academy of Sciences, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Carol L Wagner, MD  Professor of Pediatrics, Medical University of South Carolina

Carol L Wagner, MD is a member of the following medical societies: American Academy of Pediatrics, American Chemical Society, American Medical Women's Association, American Public Health Association, American Society for Bone and Mineral Research, American Society for Clinical Nutrition, Massachusetts Medical Society, National Perinatal Association, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Chief Editor

Ted Rosenkrantz, MD  Professor, Departments of Pediatrics and Obstetrics/Gynecology, Division of Neonatal-Perinatal Medicine, University of Connecticut School of Medicine

Ted Rosenkrantz, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Pediatric Society, Connecticut State Medical Society, Eastern Society for Pediatric Research, and Society for Pediatric Research

Disclosure: Nothing to disclose.

References
  1. Chamberlain PF, Manning FA, Morrison I, et al. Ultrasound evaluation of amniotic fluid volume. II. The relationship of increased amniotic fluid volume to perinatal outcome. Am J Obstet Gynecol. Oct 1 1984;150(3):250-4. [Medline].

  2. Rosenberg VA, Buhimschi IA, Dulay AT, Abdel-Razeq SS, Oliver EA, Duzyj CM, et al. Modulation of Amniotic Fluid Activin-A and Inhibin-A in Women With Preterm Premature Rupture of the Membranes and Infection-Induced Preterm Birth. Am J Reprod Immunol. Oct 13 2011;[Medline].

  3. Ben-Chetrit A, Hochner-Celnikier D, Ron M, Yagel S. Hydramnios in the third trimester of pregnancy: a change in the distribution of accompanying fetal anomalies as a result of early ultrasonographic prenatal diagnosis. Am J Obstet Gynecol. May 1990;162(5):1344-5. [Medline].

  4. Pri-Paz S, Khalek N, Fuchs KM, Simpson LL. Maximal Amniotic Fluid Index as a Prognostic Factor in Pregnancies Complicated by Polyhydramnios. Ultrasound Obstet Gynecol. Sep 5 2011;[Medline].

  5. Magann EF, Haas DM, Hill JB, Chauhan SP, Watson EM, Learman LA. Oligohydramnios, Small for Gestational Age and Pregnancy Outcomes: An Analysis Using Precise Measures. Gynecol Obstet Invest. Oct 26 2011;[Medline].

  6. Abdel-Fattah SA, Carroll SG, Kyle PM, Soothill PW. Amnioreduction: how much to drain?. Fetal Diagn Ther. Sep-Oct 1999;14(5):279-82. [Medline].

  7. Patrelli TS, Gizzo S, Cosmi E, Carpano MG, Di Gangi S, Pedrazzi G, et al. Maternal hydration therapy improves the quantity of amniotic fluid and the pregnancy outcome in third-trimester isolated oligohydramnios: a controlled randomized institutional trial. J Ultrasound Med. Feb 2012;31(2):239-44. [Medline].

  8. Cabrol D, Jannet D, Pannier E. Treatment of symptomatic polyhydramnios with indomethacin. Eur J Obstet Gynecol Reprod Biol. May 1996;66(1):11-5. [Medline].

  9. Kramer WB, Van den Veyver IB, Kirshon B. Treatment of polyhydramnios with indomethacin. Clin Perinatol. Sep 1994;21(3):615-30. [Medline].

  10. Mamopoulos M, Assimakopoulos E, Reece EA, et al. Maternal indomethacin therapy in the treatment of polyhydramnios. Am J Obstet Gynecol. May 1990;162(5):1225-9. [Medline].

  11. Desmedt EJ, Henry OA, Beischer NA. Polyhydramnios and associated maternal and fetal complications in singleton pregnancies. Br J Obstet Gynaecol. Dec 1990;97(12):1115-22. [Medline].

  12. Biggio JR Jr, Wenstrom KD, Dubard MB, Cliver SP. Hydramnios prediction of adverse perinatal outcome. Obstet Gynecol. Nov 1999;94(5 Pt 1):773-7. [Medline].

  13. Brace RA, Resnik R. Dynamics and disorders of amniotic fluid. In: Creasy RK, Resnik R, eds. Maternal-Fetal Medicine. 4th ed. 1999:632-43.

  14. Fanaroff AA, Martin RJ. Diseases of the fetus and infant. In: Neonatal-Perinatal Medicine. 6th ed. 1997:315-9.

  15. Harrison MR, Golbus MS, Filly RA. Prenatal diagnosis and treatment. In: The Unborn Patient. 2nd ed. 1990:139-49.

  16. Hill LM, Breckle R, Thomas ML, Fries JK. Polyhydramnios: ultrasonically detected prevalence and neonatal outcome. Obstet Gynecol. Jan 1987;69(1):21-5. [Medline].

  17. Jones KL. Oligohydramnios sequence. In: Smith's Recognizable Patterns of Human Malformation. 5th ed. 1997.

  18. Kilpatrick SE. Histologic prognostication in soft tissue sarcomas: grading versus subtyping or both? A comprehensive review of the literature with proposed practical guidelines. Ann Diagn Pathol. Feb 1999;3(1):48-61. [Medline].

  19. Macri CJ, Schrimmer DB, Leung A, et al. Prophylactic amnioinfusion improves outcome of pregnancy complicated by thick meconium and oligohydramnios. Am J Obstet Gynecol. Jul 1992;167(1):117-21. [Medline].

  20. Morales WJ, Talley T. Premature rupture of membranes at < 25 weeks: a management dilemma. Am J Obstet Gynecol. Feb 1993;168(2):503-7. [Medline].

  21. Phelan JP, Ahn MO, Smith CV, et al. Amniotic fluid index measurements during pregnancy. J Reprod Med. Aug 1987;32(8):601-4. [Medline].

  22. Pitt C, Sanchez-Ramos L, Kaunitz AM, Gaudier F. Prophylactic amnioinfusion for intrapartum oligohydramnios: a meta- analysis of randomized controlled trials. Obstet Gynecol. Nov 2000;96(5 Pt 2):861-6. [Medline].

  23. Rib DM, Sherer DM, Woods JR Jr. Maternal and neonatal outcome associated with prolonged premature rupture of membranes below 26 weeks' gestation. Am J Perinatol. Sep 1993;10(5):369-73. [Medline].

  24. Schumacher B, Moise KJ Jr. Fetal transfusion for red blood cell alloimmunization in pregnancy. Obstet Gynecol. Jul 1996;88(1):137-50. [Medline].

  25. Vergani P, Ghidini A, Locatelli A, et al. Risk factors for pulmonary hypoplasia in second-trimester premature rupture of membranes. Am J Obstet Gynecol. May 1994;170(5 Pt 1):1359-64. [Medline].

  26. Xiao ZH, Andre P, Lacaze-Masmonteil T, et al. Outcome of premature infants delivered after prolonged premature rupture of membranes before 25 weeks of gestation. Eur J Obstet Gynecol Reprod Biol. May 2000;90(1):67-71. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.